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BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF
ROSIGLITAZONE IN THE TREATMENT OF TYPE-2 DIABETES.
THE ITALIAN NHS PERSPECTIVE
Novelli M,Avallone A, Frizzo V, Bamﬁ F
GlaxoSmithKline,Verona,VR, Italy
OBJECTIVES: To evaluate the budget impact on the Italian NHS
of rosiglitazone based treatment strategies, compared to current
therapy. METHODS: Estimated target population for alternative
treatments was based on algorithms previously reported*. Three
groups of patients were identiﬁed to compare alternative treat-
ment strategies: 1) Rosiglitazone monotherapy vs. SU monother-
apy; 2) Rosiglitazone + metformin vs. SU + metformin; and 3)
Siglitazone + SU vs. insulin alone or in association with SU. The
perspective used was that of the Italian NHS. Time horizon was
one year. Costs/patient/year considered were: drug acquisition
costs; glycaemia self-monitoring costs; severe hypoglycaemias
costs; and clinical tests costs (according to therapy). Glycaemia
self-monitoring assumptions were based on AMD (Italian Asso-
ciation of Diabetologists) guidelines. Sensitivity analysis was per-
formed to test the robustness of the assumptions made and their
inﬂuence on the results. RESULTS: The epidemiological algo-
rithms assigned 19.84% of patients to group 1, 37.8% to group
2 and 42.36% to group 3. Treatment costs/patient/year were:
group 1–€459,91 for rosiglitazone vs. €469,06 for SU; group
2–€531,06 for rosiglitazone + metformin vs. €540,20 for SU +
metformin; group 3–€749,44 for rosiglitazone + SU vs.
€1.258,11 for insulin + SU and €1.832,97 for insulin alone. For
a hypothetical cohort of 10.000 patients, total costs were: group
1—rosiglitazone €912,460.31 vs. SU €930,581.45; group 2—
rosiglitazone + metformin €2,007,419.76 vs. SU + metformin
€2,041,944.92; group 3—rosiglitazone + SU €3,174,623.90,
insulin + SU €1,862,082.89 and insulin alone €5,051,558.94.
Total costs of Rosiglitazone based therapy were €6,094,503.97
vs. €9,886,168.20 of current treatments. CONCLUSIONS:
Rosiglitazone, when compared to alternative treatment, may
offer potential savings to the Italian NHS estimated by our model
in €3,791,664 every 10,000 diabetics per year. Savings were
mainly related to a reduction in costs of glucose self-monitoring
and insulin administration.* Drug utilization of glitazones in
Italy. ISPOR, 7th Annual European Congress.
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THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF
INSULIN GLARGINE IN POLISH SETTINGS
Kamiñski B1, Niewada M2, Latek M1, Lis J3, Gierczynski J3
1Warsaw School of Economics, Warszawa, Mazowieckie, Poland;
2Medical University of Warsaw, Warsaw, Poland; 3Sanoﬁ-Aventis
Poland, Warsaw, Poland
OBJECTIVES: To estimate incremental drug costs and savings
resulting from hypoglycemia risk reduction produced by insulin
Glargine compared to NPH insulin from payers perspective in
Poland. METHODS: Epidemiological data and expert panel
were used to evaluate the number of patients eligible for insulin
Glargine treatment in Poland. Logistic model of switching rate
from NPH insulin to insuline Glargine was developed for 3 years
time horizon for diabetes patients according to NICE guidelines.
Net drug costs reﬂect incremental acquisition costs per i.u. as
well as difference between mean daily doses of insulin Glargine
and NPH. Savings resulting from hypoglycemia risk reduction
were estimated based on literature review and unit cost of hypo-
glycemic event treatment (payers’ perspective; event associated
with hospitalization or ER visit). RESULTS: Number of patients
eligible for insuline Glargine treatment was estimated at 64 608
patients accounting for 5.48% of all diabetic patients in Poland.
Mean annual drug costs were estimated at 24.5mln EUR (PPP
value) while savings resulting from hypoglycemia risk reduction
at 4mln EUR. Subgroup showed for patients with annual hypo-
glycemia risk reduction associated with insulin Glargine 68.4%
drug acquisition expenditures, which are balanced by hypo-
glycemia treatment savings. CONCLUSIONS: Insulin Glargine
treatment was found to be budgetary neutral from payers’ per-
spective for patients with very high risk of hypoglycemia in
Poland.
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COST OF DIABETES MELLITUS TYPE-2 AND SELF
MEASUREMENT OF BLOOD GLUCOSE IN GERMANY: A
HEALTH INSURANCE PERSPECTIVE
Weber C1, Neeser K1,Wenzel H2, Schneider B3
1Institute for Medical Informatics and Biostatistics (IMIB), Basel, BS,
Switzerland; 2University of Bielefeld, Bielefeld, Germany; 3Institut für
Biometrie, Hannover, Germany
OBJECTIVES: It is extremely difﬁcult to assess the prevalence,
the total costs of Diabetes mellitus and the impact of self mea-
surement of blood glucose (SMBG) for the German health care
system. The last sound assessment of the total costs is based on
the CODE-2 study, although this study reﬂects the situation in
1998. METHODS: In this analysis we assessed the total costs of
diabetes mellitus type-2 and self measurement of blood glucose
(SMBG) for the German health care system in the year 2004,
based on the analysis of a retrospective, multicenter trial carried
out recently, dealing with the impact of SMBG on long term
patient outcomes. Our assessment is based on costs for 18 dia-
betes related complications (including surgical interventions),
follow-up-costs for these complications, costs for outpatient
physician services, cost of antidiabetic and additional pharma-
ceutical treatment and costs for strips and lancets for patients
performing SMBG. RESULTS: Overall, yearly costs for the treat-
ment of diabetes mellitus type-2 and its complications amounts
to €3489 per patient. This equals to 4.6% to 8.2% of the
German health care expenditure, in function of the estimated
prevalence of the disease in Germany. The cost difference
between the cohort with and without SMBG was not essential
(€276 higher costs in the cohort with SMBG). This cost differ-
ence should be connected with a reduction of mortality from 
4.6 to 2.7% and a reduction of non-fatal endpoints from 10.4
to 7.2% for the Non-SMBG and SMBG group respectively
reported in the underlaying study. CONCLUSIONS: From a
public health standpoint, prevention of diabetes mellitus or at
minimum prevention of its complications by optimizing glucose
metabolism should be given highest priority in times of limited
resources for health care. SMBG may be a valuable tool to
achieve this target.
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A MODEL BASED ANALYSIS OF COSTS AND EFFECTIVENESS
OF CHIROPODIST CARE IN DIABETEC PATIENTS
Habacher W1, Rakovac I1, Plank J2, Haas W2, Beck P1, Pieber TR1
1Joanneum Research, Graz, Styria, Austria; 2Medical University Graz,
Graz, Styria, Austria
OBJECTIVE: The diabetic foot is a complex late complication,
it is difﬁcult to treat and has severe impact on quality of life and
causes an enormous ﬁnancial burden for society. Aim of this
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study was to evaluate structured chiropodist care (CC) with
regard to healing rates and costs provided by intensively
instructed professionals. METHODS: One year follow-up-data
of a randomized and controlled trial (RCT) performed in the
province of Styria, Austria showed signiﬁcantly reduced reulcer-
ation rates under chiropodist care. Patients in the intervention
group received chiropodist care in average 11 times per year and
were reimbursed for the costs (€29 per visit). Based on a pub-
lished paper Austrian speciﬁc cost data of 2001 were used to
build a Markov Model to evaluate 10 years outcome. A Monte-
Carlo-Simulation (n = 10.000) was performed for patients with
chiropodist care (intervention) and no chiropodist care (control).
RESULTS: Mean follow-up-duration for 91 patients of the RCT
was 386 days with a reulceration rate of 36% in the interven-
tion group (n = 47) and 55% in the control group (p = 0.05).
The model calculation over 10 years showed treatment costs per
patient of €12,094 (SD 13,379) in the intervention and €18,538
(SD 16,120) in the control group. Costs for the general treat-
ment of diabetes were not taken into account. The amputation
rate under intervention declined to 40% versus 67% in the
control group. Taking the mean life expectancy into account (6.1
vs. 5.1ys.) average costs per patient-year were 1.985 € in the
intervention group versus €3.654 in the control group. CON-
CLUSION: The model based analysis demonstrated the beneﬁt
of CC over a 10 year period in terms of reduced amputation rates
and lower costs per patient and year.
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COSTS ASSOCIATED WITH GLUCOSE CONTROL IN THE
NON-DIABETIC CRITICALLY ILL PATIENT
Conner TM1, Bolster SR1, Rankin S1, Inman GM1, Rascati KL2
1Seton Health care Network, Austin,TX, USA; 2University of Texas at
Austin, Austin,TX, USA
OBJECTIVES: Hyperglycemia in the critically ill, non-diabetic
patient has been shown to negatively affect clinical outcomes.
Administration of continuous insulin infusion (CII) to maintain
blood glucose (BG) between 80–110mg/dL has thus become
standard of care. The objective of this study was to compare the
costs and BG levels associated with glucose control among
patients pre- and post-CII protocol implementation in an inten-
sive care unit (ICU). METHODS: Combination of time-in-
motion (TIM) observations and retrospective random chart
review to compare glucose control and costs in 2001 and 2004,
prior to and after CII implementation respectively. TIM data
determined time spent on activities related to glucose manage-
ment and chart data determined frequency of respective activi-
ties per year. Study population included ICU patients >16 years
old, mechanically ventilated for >12 hours, with no diagnosis of
diabetes. Costs were determined for glucose monitoring with no
insulin orders (2001), glucose management with sliding scale
subcutaneous insulin (2001), and management with CII proto-
col (2004) using 2005 US$ from the hospital perspective.
RESULTS: From a total 460 charts in 2001, 49 (11%) were
reviewed. From a total 540 charts in 2004, 83 (15%) were
reviewed. No differences in age, gender, marital status, or race
by year were noted (p > 0.05). Costs (mean +/-SD) associated
with monitoring and no insulin were $0.16 +/-0.56 (median =
$0.00) per patient day, with subcutaneous insulin $10.08 
+/-4.96 (median = $8.42), and with CII protocol $21.87 +/-3.90
(median = $22.49). Mean +/-SD daily blood glucose values 
were 138mg/dL +/-24, 157mg/dL +/-32, and 108mg/dL +/-10,
respectively. Regression analysis demonstrated statistical differ-
ences in BG (p < 0.01) by method. CONCLUSION: Costs asso-
ciated with CII protocol are more than twice the costs of sliding
scale subcutaneous orders per patient day, but result in recom-
mended BG values below 110mg/dL. Impact of costs on hospi-
tal policy will be discussed.
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ECONOMIC ASSESSMENT OF ADD-ON THERAPY WITH
PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN
STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND 
TYPE-2 DIABETES IN GERMANY AND SWEDEN
Berger W1, Roze S2, Palmer AJ2,Valentine WJ2, Liens D3,
Renaudin C3
1Merck KGgA, Darmstadt, Germany; 2CORE—Center for Outcomes
Research, Binningen, Basel, Switzerland; 3Merck Santé, Lyon, France
OBJECTIVES To evaluate the long-term clinical and economic
outcomes of adding Niaspan® to statin treatment in Type-2 dia-
betes patients with persistently low HDL-c. METHODS Two
models were developed to project long-term clinical and eco-
nomic beneﬁts. The ﬁrst simulated the evolution of lipid levels
with treatment utilising second order Monte Carlo methodology,
and the second was designed to calculate the risk of coronary
heart disease (CHD) events each subsequent year using standard
Markov modeling techniques. Transition probabilities for CHD
events were derived from the Framingham risk formulae. Base-
line cohort characteristics and simvastatin treatment effects were
taken from the 4S clinical trial (diabetes sub-group). Patients
with persistently low HDL-c (<1mmol/L) on statin treatment
received either add-on Niaspan® or continued statin monother-
apy. Treatment effects of Niaspan® were taken from several clin-
ical studies summarized in the European SPC. Direct costs (2004
Euros) were accounted from a third party payer perspective.
Annual discount rates of 5% (Germany) and 3% (Sweden) were
applied to clinical outcomes and costs. RESULTS A total of
23.42% of patients were projected to have persistently low
HDL-c levels after statin treatment. In these patients mean undis-
counted life expectancies of 19.72 years and 19.13 years were
projected for the Niaspan® and statin monotherapy arms respec-
tively (undiscounted difference 0.59 years). Improvements in 
discounted life expectancy were 0.26 and 0.35 years respec-
tively for Germany and Sweden. Lifetime direct medical costs
were higher by €6,038 in Germany and €6,170 (SEK 56,308) 
in Sweden with addition of Niaspan®. Incremental cost-
effectiveness ratios based on discounted life expectancies were
€23,404 in Germany and €17,538 (SEK 160,099) per life year
gained in Sweden for statin plus Niaspan® versus statin
monotherapy. CONCLUSIONS In Germany and Sweden, addi-
tion of Niaspan® to statin treatment was highly cost-effective in
Type-2 diabetes patients with persistently low HDL-c compared
to statin monotherapy.
PDB18
COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE
NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS
NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA: A UK
PERSPECTIVE
Paschen B1, Roze S2, Palmer AJ2,Valentine WJ2, Liens D3,
Renaudin C3
1Merck KGaA, Darmstadt, Germany; 2CORE—Center for Outcomes
Research, Binningen, Basel, Switzerland; 3Merck Santé, Lyon, France
OBJECTIVES: To compare the long-term cost-effectiveness of
adding Niaspan® to statin treatment in diabetic and non-diabetic
patients with persistently low HDL c. METHODS: Two models
were developed to project long-term clinical and economic out-
comes. The ﬁrst model (Monte Carlo simulation) was used to
evaluate the impact of simvastatin treatment on lipid levels and
identify patients with low HDL-c. Baseline cohort characteristics
were taken from the diabetic sub-population of the 4S study. In
